In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

Maria Souli; Flora V Kontopidou; Evangelos Koratzanis; Anastasia Antoniadou; Efthimia Giannitsioti; Pinelopi Evangelopoulou; Sofia Kannavaki; Helen Giamarellou

doi:10.1128/AAC.00322-06

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

Antimicrob Agents Chemother. 2006 Sep;50(9):3166-9. doi: 10.1128/AAC.00322-06.

Authors

Maria Souli¹, Flora V Kontopidou, Evangelos Koratzanis, Anastasia Antoniadou, Efthimia Giannitsioti, Pinelopi Evangelopoulou, Sofia Kannavaki, Helen Giamarellou

Affiliation

¹ Fourth Department of Internal Medicine, Athens University School of Medicine, University General Hospital Attikon, 124 62 Chaidari, Greece.

Abstract

The in vitro activities of tigecycline and selected antimicrobials were evaluated against a variety of multiple-drug-resistant clinical isolates, including extended-spectrum beta-lactamase- and/or metallo-beta-lactamase-producing gram-negative strains, colistin-resistant strains, vancomycin- and/or linezolid-resistant enterococci, and methicillin-resistant Staphylococcus aureus (MRSA). Tigecycline showed excellent activity against a collection of difficult-to-treat pathogens currently encountered in the hospital setting.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Cross Infection / microbiology
Drug Resistance, Multiple, Bacterial
Gram-Negative Bacteria / drug effects*
Gram-Negative Bacteria / isolation & purification
Gram-Negative Bacterial Infections / microbiology
Gram-Positive Bacteria / drug effects*
Gram-Positive Bacteria / isolation & purification
Gram-Positive Bacterial Infections / microbiology
Greece
Humans
Minocycline / analogs & derivatives*
Minocycline / pharmacology
Tigecycline

Substances

Anti-Bacterial Agents
Tigecycline
Minocycline